FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959625518> ?p ?o ?g. }

• W2959625518 endingPage "1806" @default.
• W2959625518 startingPage "1806" @default.
• W2959625518 abstract "Construction of an optimal vaccine against tumors relies on the availability of appropriate tumor-specific antigens capable to stimulate CD4+ T helper cells (TH) and CD8+ cytolytic T cells (CTL). CTL are considered the major effectors of the anti-tumor adaptive immune response as they recognize antigens presented on MHC class I (MHC-I) molecules usually expressed in all cells and thus also in tumors. However, attempts to translate in clinics vaccination protocols based only on tumor-specific MHC-I-bound peptides have resulted in very limited, if any, success. We believe failure was mostly due to inadequate triggering of the TH arm of adaptive immunity, as TH cells are necessary to trigger and maintain the proliferation of all the immune effector cells required to eliminate tumor cells. In this review, we focus on a novel strategy of anti-tumor vaccination established in our laboratory and based on the persistent expression of MHC class II (MHC-II) molecules in tumor cells. MHC-II are the restricting elements of TH recognition. They are usually not expressed in solid tumors. By genetically modifying tumor cells of distinct histological origin with the MHC-II transactivator CIITA, the physiological controller of MHC-II gene expression discovered in our laboratory, stable expression of all MHC class II genes was obtained. This resulted in tumor rejection or strong retardation of tumor growth in vivo in mice, mediated primarily by tumor-specific TH cells as assessed by both depletion and adoptive cell transfer experiments. Importantly these findings led us to apply this methodology to human settings for the purification of MHC-II-bound tumor specific peptides directly from tumor cells, specifically from hepatocarcinomas, and the construction of a multi-peptide (MHC-II and MHC-I specific) immunotherapeutic vaccine. Additionally, our approach unveiled a noticeable exception to the dogma that dendritic cells are the sole professional antigen presenting cells (APC) capable to prime naïve TH cells, because CIITA-dependent MHC-II expressing tumor cells could also perform this function. Thus, our approach has served not only to select the most appropriate tumor specific peptides to activate the key lymphocytes triggering the anti-tumor effector functions but also to increase our knowledge of intimate mechanisms governing basic immunological processes." @default.
• W2959625518 created "2019-07-23" @default.
• W2959625518 creator A5001042157 @default.
• W2959625518 creator A5008054206 @default.
• W2959625518 creator A5020886709 @default.
• W2959625518 creator A5084091903 @default.
• W2959625518 date "2019-01-01" @default.
• W2959625518 modified "2023-10-16" @default.
• W2959625518 title "CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine." @default.
• W2959625518 cites W1552951076 @default.
• W2959625518 cites W1574666429 @default.
• W2959625518 cites W1929386821 @default.
• W2959625518 cites W1938515409 @default.
• W2959625518 cites W1953171279 @default.
• W2959625518 cites W1964053616 @default.
• W2959625518 cites W1967014996 @default.
• W2959625518 cites W1971408711 @default.
• W2959625518 cites W1981933097 @default.
• W2959625518 cites W1991958666 @default.
• W2959625518 cites W1992699637 @default.
• W2959625518 cites W1993677761 @default.
• W2959625518 cites W1994305492 @default.
• W2959625518 cites W1994993231 @default.
• W2959625518 cites W2003837849 @default.
• W2959625518 cites W2006392794 @default.
• W2959625518 cites W2007717583 @default.
• W2959625518 cites W2023921578 @default.
• W2959625518 cites W2041634248 @default.
• W2959625518 cites W2046637170 @default.
• W2959625518 cites W2056526609 @default.
• W2959625518 cites W2060320549 @default.
• W2959625518 cites W2062030781 @default.
• W2959625518 cites W2069634988 @default.
• W2959625518 cites W2072541256 @default.
• W2959625518 cites W2073258270 @default.
• W2959625518 cites W2073621589 @default.
• W2959625518 cites W2074238518 @default.
• W2959625518 cites W2074857405 @default.
• W2959625518 cites W2077215378 @default.
• W2959625518 cites W2081006343 @default.
• W2959625518 cites W2083973895 @default.
• W2959625518 cites W2084596426 @default.
• W2959625518 cites W2084598886 @default.
• W2959625518 cites W2085831528 @default.
• W2959625518 cites W2086404897 @default.
• W2959625518 cites W2092191659 @default.
• W2959625518 cites W2095224412 @default.
• W2959625518 cites W2101333751 @default.
• W2959625518 cites W2105147698 @default.
• W2959625518 cites W2107857115 @default.
• W2959625518 cites W2125228907 @default.
• W2959625518 cites W2129738605 @default.
• W2959625518 cites W2133605875 @default.
• W2959625518 cites W2136710930 @default.
• W2959625518 cites W2144669901 @default.
• W2959625518 cites W2149748445 @default.
• W2959625518 cites W2152892875 @default.
• W2959625518 cites W2162455463 @default.
• W2959625518 cites W2162819001 @default.
• W2959625518 cites W2514929667 @default.
• W2959625518 cites W2557847684 @default.
• W2959625518 cites W2578528809 @default.
• W2959625518 cites W2740027623 @default.
• W2959625518 cites W2792540082 @default.
• W2959625518 cites W2890264404 @default.
• W2959625518 cites W2902817793 @default.
• W2959625518 cites W2938889495 @default.
• W2959625518 cites W3021254998 @default.
• W2959625518 cites W62176468 @default.
• W2959625518 doi "https://doi.org/10.3389/fimmu.2019.01806" @default.
• W2959625518 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6682709" @default.
• W2959625518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31417570" @default.
• W2959625518 hasPublicationYear "2019" @default.
• W2959625518 type Work @default.
• W2959625518 sameAs 2959625518 @default.
• W2959625518 citedByCount "53" @default.
• W2959625518 countsByYear W29596255182019 @default.
• W2959625518 countsByYear W29596255182020 @default.
• W2959625518 countsByYear W29596255182021 @default.
• W2959625518 countsByYear W29596255182022 @default.
• W2959625518 countsByYear W29596255182023 @default.
• W2959625518 crossrefType "journal-article" @default.
• W2959625518 hasAuthorship W2959625518A5001042157 @default.
• W2959625518 hasAuthorship W2959625518A5008054206 @default.
• W2959625518 hasAuthorship W2959625518A5020886709 @default.
• W2959625518 hasAuthorship W2959625518A5084091903 @default.
• W2959625518 hasBestOaLocation W29596255181 @default.
• W2959625518 hasConcept C147483822 @default.
• W2959625518 hasConcept C147969180 @default.
• W2959625518 hasConcept C154317977 @default.
• W2959625518 hasConcept C167672396 @default.
• W2959625518 hasConcept C170627219 @default.
• W2959625518 hasConcept C193419808 @default.
• W2959625518 hasConcept C202751555 @default.
• W2959625518 hasConcept C203014093 @default.
• W2959625518 hasConcept C207936829 @default.
• W2959625518 hasConcept C2775890610 @default.
• W2959625518 hasConcept C2776090121 @default.

• next